Cullinan Therapeutics Inc
CGEM7.640USD
-0.030-0.39%
交易中 （美东）报价延迟15分钟
448.48M总市值
亏损市盈率 TTM
关于 Cullinan Therapeutics Inc 公司
Cullinan Therapeutics, Inc.（前身为 Cullinan Oncology, Inc.）是一家专注于开发与模式无关的靶向疗法的生物制药公司。该公司拥有一系列临床阶段资产，可抑制疾病的关键驱动因素或利用免疫系统消除肿瘤和自身免疫性疾病中的患病细胞。其产品线包括 CLN-619、CLN-978、Zipalertinib (CLN-081/TAS6417)、CLN-049、CLN-418 和 CLN-617。其领先的非合作项目 CLN-619 是一种人源化 IgG1 单克隆抗体 (mAb)，可与应激诱导配体 MICA 和 MICB (MICA/B) 结合，这些配体在多种实体瘤和血液系统恶性肿瘤中表达。 CLN-978 是一种新型、高效、半衰期延长的 CD19xCD3 双特异性 T 细胞接合构建体。CLN-081/TAS6417 是一种新型、口服、突变表皮生长因子受体 (EGFR) 共价抑制剂。CLN-049 是一种 FLT3xCD3 T 细胞接合双特异性抗体。CLN-418 是一种 B7H4 x 4-1BB 双特异性免疫激活剂。
公司简介
公司代码CGEM
公司名称Cullinan Therapeutics Inc
上市日期Jan 08, 2021
CEOMr. Nadim Ahmed
员工数量111
证券类型Ordinary Share
年结日Jan 08
公司地址One Main Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编02142
电话16174104650
网址https://cullinantherapeutics.com/
公司代码CGEM
上市日期Jan 08, 2021
CEOMr. Nadim Ahmed
公司高管
名称
名称/职务
职务
持股
持股变动
Ms. Corinne Savill, Ph.D.
Ms. Corinne Savill, Ph.D.
Chief Business Officer
Chief Business Officer
240.99K
+18.43%
Dr. Jennifer Michaelson, Ph.D.
Dr. Jennifer Michaelson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
142.00K
+48.29%
Mr. Nadim Ahmed
Mr. Nadim Ahmed
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.03K
-64.17%
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Mr. David Meek
Mr. David Meek
Independent Director
Independent Director
--
--
Dr. Anne-Marie (Annie) Martin, Ph.D.
Dr. Anne-Marie (Annie) Martin, Ph.D.
Independent Director
Independent Director
--
--
Ms. Mary Kay Fenton
Ms. Mary Kay Fenton
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer
--
-100.00%
Dr. David P. Ryan, M.D.
Dr. David P. Ryan, M.D.
Independent Director
Independent Director
--
--
Mr. Stephen W. Webster
Mr. Stephen W. Webster
Independent Director
Independent Director
--
--
Ms. Jacquelyn (Jackie) Sumer
Ms. Jacquelyn (Jackie) Sumer
Chief Legal and Compliance Officer, Company Secretary
Chief Legal and Compliance Officer, Company Secretary
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Ms. Corinne Savill, Ph.D.
Ms. Corinne Savill, Ph.D.
Chief Business Officer
Chief Business Officer
240.99K
+18.43%
Dr. Jennifer Michaelson, Ph.D.
Dr. Jennifer Michaelson, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
142.00K
+48.29%
Mr. Nadim Ahmed
Mr. Nadim Ahmed
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
68.03K
-64.17%
Ms. Mary T. Thistle, CPA
Ms. Mary T. Thistle, CPA
Independent Director
Independent Director
--
--
Mr. David Meek
Mr. David Meek
Independent Director
Independent Director
--
--
Dr. Anne-Marie (Annie) Martin, Ph.D.
Dr. Anne-Marie (Annie) Martin, Ph.D.
Independent Director
Independent Director
--
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 7月2日 周三
更新时间: 7月2日 周三
持股股东
股东类型
持股股东
持股股东
占比
MPM BioImpact LLC
12.96%
BVF Partners L.P.
9.74%
Deerfield Management Company, L.P.
6.54%
BlackRock Institutional Trust Company, N.A.
6.45%
Lynx1 Capital Advisors LLC
5.45%
Other
58.85%
持股股东
持股股东
占比
MPM BioImpact LLC
12.96%
BVF Partners L.P.
9.74%
Deerfield Management Company, L.P.
6.54%
BlackRock Institutional Trust Company, N.A.
6.45%
Lynx1 Capital Advisors LLC
5.45%
Other
58.85%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
33.90%
Hedge Fund
33.37%
Investment Advisor
31.32%
Private Equity
5.96%
Corporation
3.34%
Research Firm
3.10%
Venture Capital
2.41%
Individual Investor
1.93%
Bank and Trust
0.21%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
322
71.66M
121.43%
-11.90M
2025Q1
338
72.87M
123.61%
-11.39M
2024Q4
327
73.40M
125.57%
-6.51M
2024Q3
314
72.11M
124.54%
-3.79M
2024Q2
302
70.01M
121.57%
+16.71M
2024Q1
279
46.56M
104.64%
-7.05M
2023Q4
270
43.35M
97.85%
-6.38M
2023Q3
266
43.12M
99.67%
-8.64M
2023Q2
263
42.81M
108.75%
-4.67M
2023Q1
257
38.30M
97.36%
-9.36M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
MPM BioImpact LLC
7.65M
12.96%
--
--
Apr 01, 2025
BVF Partners L.P.
5.75M
9.74%
--
--
Mar 31, 2025
Deerfield Management Company, L.P.
3.86M
6.54%
+481.44K
+14.25%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.81M
6.45%
-103.34K
-2.64%
Mar 31, 2025
Lynx1 Capital Advisors LLC
3.22M
5.45%
+1.96M
+155.66%
Mar 31, 2025
The Vanguard Group, Inc.
3.03M
5.14%
+103.50K
+3.53%
Mar 31, 2025
Citadel Advisors LLC
2.75M
4.66%
+64.24K
+2.39%
Mar 31, 2025
Blue Owl Capital Holdings LP
2.44M
4.13%
+65.00K
+2.74%
Mar 31, 2025
Kynam Capital Management LP
2.34M
3.96%
+1.09M
+86.68%
Mar 31, 2025
Franklin Advisers, Inc.
2.20M
3.73%
+18.42K
+0.84%
Mar 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
0.76%
Tema Oncology ETF
0.54%
iShares Micro-Cap ETF
0.09%
SPDR S&P Biotech ETF
0.07%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Avantis US Small Cap Equity ETF
0.05%
Direxion Daily S&P Biotech Bull 3X Shares
0.04%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.03%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比0.76%
Tema Oncology ETF
占比0.54%
iShares Micro-Cap ETF
占比0.09%
SPDR S&P Biotech ETF
占比0.07%
Invesco Nasdaq Biotechnology ETF
占比0.05%
ProShares Ultra Nasdaq Biotechnology
占比0.05%
Avantis US Small Cap Equity ETF
占比0.05%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.04%
iShares Biotechnology ETF
占比0.03%
iShares Russell 2000 Value ETF
占比0.03%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
